Redeye provides an in-depth update on AcouSort following the company’s Q3 report. We view the report as broadly undramatic and in line with expectations, aside from slightly softer revenues than anticipated. We also take a positive view of the recent news flow, which includes a new evaluation agreement with SeeQ Diagnostics and continued progress with the central European collaboration partner. We reiterate our base case and fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/